

Summer Brook Dewdney, M.D.
Director, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology
Associate Professor, Division of Gynecologic Oncology
Rush University Medical Center

PERSONAL INFORMATION

Date of Birth: 03/14/1977
Citizenship: United States

Home Address: 163 N. Euclid
Oak Park, IL 60302
Telephone: (312) 401-8787

Office Address: Rush University Medical Center
Division of Gynecologic Oncology
1725 West Harrison Street Suite 842 Chicago, IL 60612
Telephone: (312) 942-6312 Fax: (312) 942-7261
Email: summer_dewdney@rush.edu

EDUCATION

FELLOWSHIP

Washington University
Division of Gynecologic Oncology

St. Louis, MO
July 2008-June 2011

RESIDENCY

University of Chicago Hospitals
Department of Obstetrics and Gynecology

Chicago, IL
June 2004-June 2008

MEDICAL SCHOOL

University of Iowa College of Medicine
Doctor of Medicine

Iowa City, IA
July 2000-May 2004

UNDERGRADUATE

Miami University
Bachelor of Arts in Zoology with Minor in Neuroscience

Oxford, OH
August 1995-May 1999

LEADERSHIP TRAINING

LeadQuest Faculty Leadership Development Program
Rush University Medical Center

2013

5/12/23
SM

-Selected physicians were asked by Dean to participate in leadership training, this consisted of weekly leadership sessions during a 4 month period, we underwent leadership training.

ACADEMIC APPOINTMENTS

Rush University Medical Center

Chicago, IL

Assistant Professor

Division of Gynecologic Oncology

Department of Obstetrics and Gynecology

August 2011 - present

ADMINISTRATIVE TITLES

Rush University Medical Center

Patient Safety Officer, Gynecology, Department of Obstetrics and Gynecology

2014-present

Committee Chair, Robotic Surgery Quality Committee, Appointed by Surgical Executive Committee

2017-present

Director of research trials for division of Gynecologic Oncology

2015-present

CERTIFICATION AND LICENSURE

Medical License: State of Illinois, Active

State of Missouri, Active

Illinois Controlled Substances, State of Illinois, Active

DEA Certificate, United States Drug Enforcement Agency, Active

BOARD/SPECIALTY

Fellow, American Board of Obstetrics and Gynecology

2012-present

Fellow, American Board of Obstetrics and Gynecology, Gynecologic Oncology

2014-present

HOSPITAL PRIVILEGES

Saint James Franciscan Alliance

2016-present

Metro South Medical Center

2012-present

Swedish Covenant Hospital

2016-present

Rush Copley Medical Center

2018-present

Rush University Surgicenter

2017-present

Rush University Medical Center

2011-present

HONORS AND AWARDS

IL Top Doctor , awarded	2020, 2021, 2022
Chicago Magazine, "Top Doctor" , October 2019 issue, Best Oncologist	October 2019
Chicago Magazine, "Top Doctor" , June 2019 issue, "Top Doctor" for women	June 2019
SCORE Positive Learning Environment Award Nomination , Rush University Medical Center	2017
Wow Award! Nominated by patient family member Institutional award given by employees of Rush University to other employees or exceptional performance, I was nominated by a patient's family member who was an employee.	May 2016
Young Doctors Summit award , International Gynecologic Cancer Society I was nominated by a colleague and won a travel award to this international conference, joining other international young gynecologic oncologists.	October 2012
First place award for scientific presentation , St. Louis Gynecologic Society I won the city wide annual first place award for the best scientific presentation.	April 2009
Chief Resident , Department of Obstetrics and Gynecology, University of Chicago Hospitals	2007-2008
Galloway Fellowship , Memorial Sloan Kettering Cancer Center I was accepted to attend an away rotation on the gynecologic surgical service during my residency, received "honors"	February 2007
Chicago Lying-In Hospital Excellence in Student Teaching I received this award for excellence in teaching, one resident per year received this award	2004
Honors program , Miami University	1995-1999

LEADERSHIP SERVICE/LEADERSHIP POSITIONS

National Level

Chair of Society of Gynecologic Oncology (SGO) National Registry, Clinical Outcomes
Registry (COR) (2014-present)

SM

I started the pilot and then implemented a nationwide registry for SGO, the clinical outcomes registry, during this time we obtained MOC credit from ABOG, collaborated with ASCO's CancerlinQ, and created a workplace to test out NQF measures for gynecologic oncology. We have just completed a validation of the registry funded grant from Intuitive Surgical, we are now creating a protocol to open the database to our membership.

SGO liaison, American College of Surgeons, Commission on Cancer (COC) (2019-present)

I am the representative for SGO to the COC, I currently serve on the Quality Improvement Committee, this is an appointment from the SGO president and executive committee.

Chair of SGO quality measures and outcomes committee (2020-present)

After being a successful member and vice chair, I was asked to be chair of this committee. We will continue our work on patient reported outcomes, a national registry and creating collaborations.

Vice Chair of SGO quality measures and outcomes committee (2018-2020)

I have worked on many projects during my time, including writing a white paper on patient reported outcomes for the society, continuing the national registry, implementing gynecologic measures in American College of Surgeons Commission on Cancer.

Member, SGO quality measures and outcomes committee (2014-present)

Proposed to committee the implementation of gynecologic cancers to the CO presented to the American College of Surgeons COC, and measures were accepted and continued to be used today.

American College of Obstetrics and Gynecology (ACOG), Women's Health Registry Alliance committee member (2014-present)

Vice Chair (2016-present)

I was SGO's liaison to this committee, we identified gaps in registries within the field of obstetrics and gynecology, also worked on creating universally accepted datapoints.

ASCO, Oncology Leadership Council for CancerlinQ, member (2016-present)

I represent SGO on this council of approximately 20 members who advise ASCO on CancerlinQ. Other members of this council include stakeholders, such as FDA, NIH, CAP ASTRO, Pharma, other societies. CancerLinQ is ASCO's database initiative for rapid learning in oncology.

SGO Healthcare, Social and Economic Policy committee member (2015-present)

American College of Surgeons, Commission on Cancer (COC), SGO initiative and then lead spearhead to include gynecologic measures, presented and were accepted May 2014
These measures are now implemented nationwide.

Regional/local

Equal Hope, non-for-profit, located in Chicago (formerly known as the Metropolitan Breast Cancer Taskforce of Chicago) (2018-present)

I initiated and now am committee chair for the taskforce to eradicate cervical cancer in Chicago. Our committee has recruited stakeholders in cervical cancer city wide, including university and community hospitals, physicians, nurse navigators, community leaders. We are leading an effort to eradicate cervical cancer through vaccination, prevention, and quality in treatment.

Equal Hope, Board member (2019- present)

Serve on the board of directors for Equal Hope

Institutional level

Member of search committee for Obstetrics and Gynecology Chair (2019)

Selected to be member for this search committee

Chair of Robotic committee (2017-present)

Lead the committee in the acquirement of the Xi robot in 2018 fiscal year, worked on schedules, privileging for surgeons, served as a liaison between surgical/perioperative administration and robotic surgeons. Now leading another initiative to purchase both Xi and SP robot in coordination with other committee members.

Cancer Liaison Physician (CLP) for Rush University Medical Center Cancer Committee, to the COC (American College of Surgeons) (2013-2019)

Appointed by Cancer center committee chair to serve 2 three-year terms as the CLP for Rush University Medical Centers Cancer Committee which is responsible for maintaining Rush's accreditation with this organization. I helped Rush obtain a certification in 2014, and then another site visit in 2017.

Patient Safety Officer (2014-present), gynecology

I manage the quality and safety for gynecology, this includes implementing new quality initiatives include SSI, and ERAS programs here at Rush University Medical Center. In addition, evaluate safety events when reported, and making recommendations to the Ob/gyn executive committee. We have successfully decreased surgical site infections over the past 4 years.

Implementation of seamless MD into gynecologic oncology.

Chair of Gyn Quality committee (2014-present)

Chair our monthly QI meetings.

Member of Surgical Quality Committee (2014-present)

I served as the gynecology representative to this committee.

Physician Director of 9Kellog (2013-2017)

Appointed by CMO, to be the physician liaison for this unit, managed any issues between nursing and physicians including communication and education with nursing and staff.

Member of Cancer Center Section Leaders committee (2013-2016)

Represented gynecologic oncology, committee was used for collaboration between divisions that served cancer patients.

Translational Cancer Research committee (Dr. Mulshine) (2013-2015)

Weekly meetings with stakeholders performing translational research at Rush University medical center, including presenting my own translational research from fellowship, collaborated with basic science researchers.

Member of Operative and Invasive committee (2012-2015)

Served as a member on this committee that met monthly to determine the needs of purchasing for the operating rooms.

Initiated Rush as an alpha site for SGO COR Registry (2014)

Organized Rush as one of the first participants of the SGO Registry, stipend \$10,000.

Search committee for Rush's Cancer Center Director (2014)

Selected as member for search committee.

Bears Care Research project in breast and endometrial cancer (2014)

Research proposal in coordination with Dr. Rao.

Member of ORVAC committee (2012-2013)

Served as a member of the committee, which decided on surgical purchases at Rush University Medical Center.

SOCIETY MEMBERSHIPS

Society of Gynecologic Oncology	2008 - present
American College of Obstetricians and Gynecologists	2004 - present
American Society of Clinical Oncology	2008 -present
International Gynecologic Cancer Society	2011-present

TEACHING

Rush University Medical Center: Daily clinical teaching of residents and medical students on service, twice monthly didactics for trainees on service, quarterly lectures to Ob/Gyn residents

Mentorship to students/residents/trainees/fellows:

Research advisor to Karina Oelerich, (Rush University Medical student,) 2018-present, project examining cervical cancer disparities in Chicago, Illinois, ongoing

- Oelerich, K, Oshomuvwe D, Munoz K, Lee NL, Ansell D, Murphy A, Dewdney S. Neighborhood Barriers associated with Cervical Cancer Screening in Chicago, IL. Abstract Podium Presentation, 37th Annual Rush University Forum for Research and Clinical Investigation, Chicago IL March, 2020

Research advisor to Qudsia Haque, (Rush University Ob/Gyn resident), 2018-present, NCDB project examining neoadjuvant therapy in advanced endometrial cancer, ongoing

Research advisor and mentor to Larissa Mattei (Rush University Ob/Gyn resident), 2018-present, NCDB project examining disparities in cervical cancer, ongoing

- Mattei LH, Sighoko D, Lee NK, Ansell D, **Dewdney SB**. Racial disparities in survival by in patients with cervical cancer. The Society of Gynecologic Oncology's Clinical Outcome Registry database validation process. 51th Annual Meeting on Women's Cancer. Society of Gynecologic Oncology, Toronto, Ontario, Canada March 2020
- Mattei LH, Sighoko D, Lee NK, Ansell D, **Dewdney SB**. Racial disparities in survival by stage and histology in patients with cervical cancer. The Society of Gynecologic Oncology's Clinical Outcome Registry database validation process. 51th Annual Meeting on Women's Cancer. Society of Gynecologic Oncology, Toronto, Ontario, Canada March 2020

Mentor and research advisor to Erica Huelsman (Rush University Medical student), 3 paper submissions (2 accepted), 2014-present;

- Huelsmann E, Zighelboim I, Ahmed A, **Dewdney S**. The role of neoadjuvant chemotherapy in the management of patients with advanced ovarian cancer: survey results from members of the society of gynecologic oncology, a 5-year follow up. *Gynecol Oncol Rep*. 2017 16;20:47-50
- Huelsmann E, Tosto A, **Dewdney S**. Pharmaceuticals account for the majority of actual cost of care from diagnosis to death in the treatment of ovarian cancer. *J Gynecol Women Health*. 2018 1:103

Research advisor to Channing Burks (Rush University Ob/Gyn resident), robotic surgery project, 2014-2017

- Burks C, Nelson L, Kumar D, Fogg L, Guirguis A, Rotmensch J, **Dewdney S**. Evaluation of complications robotic assisted gynecologic surgery. *J Minimally Invasive Gynecology*. 2017 Feb;24(2):280-28

Research advisor to Amanda Dhuyvetter (Ob/Gyn Resident), NCDB project on endometrial cancer, 2014-2016

Research advisor to Victoria Gonzalez (Rush University Medical student), endometrial cancer project with a resident, breast/cervical cancer project, 2014-2016

- Gonzalez V, Petersen L, Ghai R, **Dewdney S**, Madrigano A. Recurrent cervical cancer presenting as inflammatory breast cancer. *Am Surg*. 2016 Sep;82;(9)275-7

Research advisor and mentor to Darren Dolly (Rush University Ob/Gyn Resident), endometrial cancer project, 2013-2016

- Dolly D, Mihai A, Rimel BJ, Fogg L, Rotmensch J, Guirguis A, Yordan E, **Dewdney S**. Diagnosis to treatment is associated with a decreased survival for patients with endometrial cancer. *Front Oncol* 2016 Feb 12;6:31.

Research advisor to Andi Mihai (Rush University Medical student), endometrial cancer project, 2013-2016

- Dolly D, Mihai A, Rimel BJ, Fogg L, Rotmensch J, Guirguis A, Yordan E, **Dewdney S**. Diagnosis to treatment is associated with a decreased survival for patients with endometrial cancer. *Front Oncol* 2016 Feb 12;6:31.

Research advisor and mentor to Michelle Beck, (Rush University Ob/Gyn resident), ERAS project, presented at resident research day, 2016

COMMUNITY SERVICE

- Speaker for Bright Pink (2015- 2016)
 - Lectures to spread awareness about signs and symptoms of ovarian cancer
 - Unity Point Health-Trinity, Bettendorf, Iowa (April, 2016)
 - University of Iowa Hospitals and Clinics, Iowa City, Iowa (October, 2015)
 - Chicago Latino Network, Community lecture, Chicago, Illinois (January, 2012)
- Community lecture, West Suburban Hospital, December 2016. BRCA and surgery for Ovarian Cancer
- Community lecture, West Suburban Hospital, August 2016. Robotics in Gynecologic Oncology
- Community lecture, Gottlieb Hospital, February 2013. HPV and Cervical cancer screening
- Community lecture, Swedish Covenant Hospital, March 2012. Robotics in Gynecologic Oncology

- Community lecture, St. Catherine's hospital, October 2012. Robotics in Gynecologic Oncology
- Community lecture, Adventist LaGrange Memorial Hospital, October 2012. HPV and Cervical Cancer Screening
- Community lecture, Norwegian Hospital, January 2013. Robotics in Gynecologic Oncology

CLINICAL SERVICE

2011-present

Assistant professor
Department of Obstetrics and Gynecology
Division of Gynecologic Oncology
Rush University Medical Center
Chicago, Illinois

I see approximately 60-80 patients per week, with an average of 8-10 news, and perform 5-10 surgeries a week, over the past 4 years, exceeded my RVU target by ~35%.

SCIENTIFIC AND SCHOLARLY ACTIVITIES

Reviewer for Professional Journal

Gynecologic Oncology
Journal of Gynecologic Oncology
International Journal of Gynecologic Cancer

Editorial Boards

Editorial board, Hemonc.org
Section editor of Gynecologic Oncology (2018-present)

Editorial board, Cancer commons
Section editor of Gynecologic Oncology (2018-present)

Invited Seminars and Lectures

Invited lecturer, University of Chicago, CLIER, Updated in Obstetrics and Gynecology CME program

Dewdney S. BRCAness and Ovarian Cancer, Chicago, Illinois, Sept 2016

Invited lecturer and panel discussion, Northwestern University, Chicago, Illinois
Ovarian Cancer Survivors day, Chicago Illinois

- "Navigating treatment if your cancer recurs" 2019
- "Navigating treatment if your cancer recurs" 2017
- "Navigating treatment if your cancer recurs" 2015
- "Navigating treatment if your cancer recurs-What are my treatment options?"

- 2013
- “Addressing your risk” 2011

Invited lecturer SGO Allied Health Professionals Workshop, Chicago, Illinois

- Dewdney S. “Risk reducing surgery and genetic screening” 2014
- Dewdney S. “Updates in the standard of care” 2016

Grand rounds

- Visiting professor
Dewdney S. Quality measures, Registry, Big Data, Cure? University of Chicago, Resident research day, Visiting Professor, Chicago, Illinois, 2017
- **Dewdney S.** *Karkinos to Carcinoma: A Brief History of Cancer*. Washington University. St. Louis, MO, 2011
- **Dewdney S.** *Living at the End of Life*. Grand rounds presentation. Department of Obstetrics and Gynecology, University of Chicago Hospitals, Chicago, IL, 2008.
- **Dewdney S.** *Adhesion Prevention: What is the Efficacy of Seprafilm?* Grand rounds presentation with visiting professor David Grimes, MD. Department of Obstetrics and Gynecology, University of Chicago Hospitals, Chicago, IL, 2006.

Invited Presentations at Regional, National, and International Meetings

Dewdney S. High accrual of patients to NRG trials at our institution. NRG semi-annual national meeting, Houston, TX, January 2020

Dewdney S. So now you know...how to incorporate quality measures into your practice. Presentation, 47th Annual Meeting on Women’s Cancer. Society of Gynecologic Oncology, San Diego, California, March 2016

Course director. Quality measures and outcomes. 47th Annual Meeting on Women’s Cancer. Society of Gynecologic Oncology, San Diego, California, March 2016

Dewdney S. Invited lecturer: *Karkinos to Carcinoma: A Brief History of Cancer*. Society of Gynecologic Nurse Oncologist annual meeting symposium, Memphis, TN, 2012

NATIONAL CLINICAL TRIALS

NRG/Gynecologic Oncology Group (GOG)

Active/Pending/Hold

NRG-GY-018-A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
Site PI for Rush University Medical Center

NRG GY012-Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combination of Cediranib/Olaparib in Women with Recurrent, Persistent or Metastatic Endometrial Cancer
Site PI for Rush University Medical Center

NRG GY004-Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Site PI for Rush University Medical Center

NRG-GY005 MD choice of Non-platinum Regimen versus Cediranib versus Olaparib versus Olaparib/Cediranib in Recurrent Ovarian Cancer
Site PI for Rush University Medical Center

Closed

GOG 212-A Randomized Phase III Trial Of Maintenance Chemotherapy Comparing 12, Monthly Cycles Of Single Agent Paclitaxel Or CT-2103 Versus No Treatment Until Documented Relapse In Women With Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer Who Achieve A Complete Clinical Response To Primary Platinum/Taxane Chemotherapy
Site PI for Rush University Medical Center

GOG 277-A Phase III Randomized Trial of Gemcitabine plus Docetaxel Followed by Doxorubicin versus Observation for Uterus-Limited, High-Grade Uterine Leiomyosarcoma Measurable or non-measurable Stage IVB or Recurrent Endometrial Cancer
Site PI for Rush University Medical Center

GOG 268-A Phase II Evaluation of Temsirolimus in Combination with Carboplatin and Paclitaxel followed by Temsirolimus Consolidation as First-line Therapy in the Treatment of Clear Cell Carcinoma of the Ovary
Site PI for Rush University Medical Center

GOG 274 OUTBACK TRIAL-A Phase III Randomized Trial of adjuvant chemotherapy following chemo-radiation as primary treatment for locally advanced cervical cancer compared to chemo-radiation alone
Site PI for Rush University Medical Center

GOG 258- A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Cancer

Site PI for Rush University Medical Center

GOG 225-Can Diet and Exercise modulate ovarian, fallopian tube, and primary peritoneal cancer progression free survival?

Site PI for Rush University Medical Center

GOG 260-Phase II evaluation of elesclomol sodium and weekly Taxol for Advanced Endometrial Cancer

Site PI for Rush University Medical Center

GOG-277-A Phase III Randomized Trial of Gemcitabine plus Docetaxel Followed by Doxorubicin versus Observation for Uterus-Limited, High-Grade Uterine Leiomyosarcoma

Site PI for Rush University Medical Center

NRG CC002-Pre-Operative Assessment and Post-Operative Outcomes of Elderly Women With Gynecologic Cancers

Site PI for Rush University Medical Center

GOG Partners

Active/Pending/Hold

GOG 3036- A Phase II Study Of Tazemetostat (Epz-6438) (IND # 138671) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of The Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma

GOG 3018-The OVAL Study: A Randomized Controlled, Double-arm, Double Blind, of Ofranergene Obadenovec (VB-111) Combined with Paclitaxel versus Paclitaxel Combined With Placebo

Site PI for Rush University Medical Center

GOG 3015-A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (IMagyn050)

Site PI for Rush University Medical Center

GOG 3003-A Randomized Double-Blind Placebo-Controlled Phase II Study of VTX-2337 in Combination with PLD in Patients with recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal

Site PI for Rush University Medical Center

Closed

GOG 3012-A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
Site PI for Rush University Medical Center

GOG 3005- A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel with or without Concurrent and Continuation Maintenance Veliparib (PARP Inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Site PI for Rush University Medical Center

Pharma

Active/Pending/Hold

HPV-201 - A Phase 2, Randomized, Open Label, Efficacy Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation with Celectra™ 2000 Alone or in Combination with Imiquimod, for HPV-16 and/or HPV-18 Related High Grade Squamous Intraepithelial Lesion (HSIL) of the Vulva
Site PI for Rush University Medical Center

ENGOT-ov50 / INNOVATE-3: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 200kHz) Concomitant with Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer

Closed

Farletuzumab/MORAb-003-011-A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab in Combo with Carbo + Taxol or Carbo + PLD in Subjects with Low CA125 Platinum-Sensitive Ovarian Cancer
Site PI for Rush University Medical Center

Janssen ET743-OVC-3006-Phase III Randomized, Open-Label Study Comparing the Combination of Yondelis and Doxil/Caelyx with Doxil/Caelyx Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal or Fallopian Tube
Site PI for Rush University Medical Center

VX-EC-2-02: A Phase II, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction with Progestin Therapy in Patients with Endometrial Carcinoma
Site PI for Rush University Medical Center

Other

Active

UC13-1235-A Randomized Placebo Controlled Phase II Trial of Metformin in Conjunction with Chemotherapy Followed by Metformin Maintenance in Advanced Stage Ovarian, Fallopian Tube and Primary Peritoneal Cancer (with macroscopic residual)

Site PI for Rush University Medical Center

SWOG

Active

SWOG-Prospective Comparative effectiveness trail for malignant bowel obstruction

Site PI for Rush University Medical Center

BIBLIOGRAPHY

Google scholar h-index score-12, i10 index -13

Scopus h-index score-8

Peer-Reviewed Publications

1. Sisodia RC, **Dewdney SB**, Fader AN, Wethington SL, Melamed A, Von Gruenigen VE, Zivanovic O, Carter J, Cohn DE, Huh W, Wenzel L, Doll K, Cella D, Dowdy SE. Patient reported outcomes measures in gynecologic oncology: A primer for clinical use, Part I. *Gynecologic Oncology*. Submitted January 2020.
2. Ansari S, Liao Y, **Dewdney S**, Wang D, Barry P. Vaginal oligometastatic disease of colorectal primary: a novel therapeutic approach. *Rare Tumors*. Submitted July, 2019.
3. Tollkuci E, Chalmers A, Schultz K, **Dewdney S**, Basu S, Usha L. Carboplatin desensitization efficacy in gynecologic oncology patients. *Journal of Hematology Oncology Pharmacy*. 2020;10(2);XX-XX www.JHOPonline.com.
4. Shammo JM, Usha L, Rishardson K, Elliot EJ, **Dewdney S**, Venugopal P, Cobleigh M, Kuzel TM. Olaparib-induced severe folate deficiency in a patient with advanced ovarian cancer. *J Onco Practice*. 15, no.7 (July 1 2019) 405-407. PMID 31199709
5. Monk BJ, Kauderer JT, Moxley KM, Bonebrake AJ, **Dewdney SB**, Alvarez Secord, A, Ueland FR, Johnston CM, Aghajanian CA, Monk BA. A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer: an NRG Oncology/Gynecologic Oncology Group Study. *Gynecol Oncol*. 2018 Dec;151(3):422-427. PMID 30309721
6. Sharma PS, **Dewdney SB**, Trohman RT. An Unusual Electrocardiogram. *Pediatric Cardiology*. 2018 Dec;39(8):117-1718. PMID 30232513

7. ***Dewdney SB**, Dancisak AC, Lachance JA, Grendys EC, Dowdy SC, Powell M, SChorge JO. Society of Gynecologic Oncology Clinical Outcomes Registry: From small beginnings come great things. *Gynecologic Oncology*. 2018;148(3):439-444. PMID 28317007
8. Huelsmann E, Tosto A, **Dewdney S**. Pharmaceuticals account for the majority of actual cost of care from diagnosis to death in the treatment of ovarian cancer. *J Gynecol Women Health*. 2018 1:103.
9. Huelsmann E, Zighelboim I, Ahmed A, **Dewdney S**. The role of neoadjuvant chemotherapy in the management of patients with advanced ovarian cancer: survey results from members of the society of gynecologic oncologist, a 5-year follow up. *Gynecol Oncol Rep*. 2017 Feb 16;20:47-50. PMID 20673970
10. Shammo JM, Usha L, Richardson K, Elliot EJ, Venugopal P, Kuzel TM, Cobleigh M, **Dewdney S**. First report of severe folate deficiency in women treated with olaparib for relapsed ovarian cancer. *Blood* 2017 130:4748
11. **Dewdney S**, Lachance J. Electronic records, registries and the development of "Big Data": crowd sourcing quality towards cures. *Front Oncol*. 2017 Jan 30;6:268. PMID 28194369
12. Burks C, Nelson L, Kumar D, Fogg L, Guirguis A, Rotmensch J, **Dewdney S**. Evaluation of complications robotic assisted gynecologic surgery. *J Minimally Invasive Gynecology*. 2017 Feb;24(2):280-285. PMID 27836798
13. Gonzalez V, Petersen L, Ghai R, **Dewdney S**, Madrigano A. Recurrent cervical cancer presenting as inflammatory breast cancer. *Am Surg*. 2016 Sep;82(9):275-7. PMID 27670547
14. Usha L, **Dewdney SB**, Buckingham LE. Tumor Screening and DNA Testing in the Diagnosis of Lynch Syndrome. *JAMA*. 2016;316 (1):93-96. PMID 27380347
15. Temkin SM, Tanner EJ, **Dewdney SB**, Minasian LM. Reducing overtreatment in gynecologic oncology: The case for less in endometrial and ovarian cancer. *Front Oncol*. 2016 May 9;6:118. Review. PMID 27242958
16. Dolly D, Mihai A, Rimel BJ, Fogg L, Rotmensch J, Guirguis A, Yordan E, **Dewdney S**. Diagnosis to treatment is associated with a decreased survival for patients with endometrial cancer. *Front Oncol* 2016 Feb 12;6:31. PMID 26904507
17. **Dewdney SB**, Jiao Z, Roma AA, Gao F, Rimel BJ, Thaker PH, Powell MA, Massad LS, Mutch DG, Zighelboim I. The prognostic significance of lymphovascular space invasion in laparoscopic versus abdominal hysterectomy for endometrioid endometrial cancer. *Eur J Gynaecol Oncol*. 2014;35(1):7-10.



18. Lamzabi I, Buckingham L, Gebrekristos M, Jain R, Gattuso P, Reddy V, Guirguis A, **Dewdney S**, Rotmensch J, Bitterman P. Use of cervical mucus to screen for gynecologic malignancies: a pilot study. *Mod Pathol* 2013;Nov(11):1508-13. PMID 23765243
19. Blanco LZ, Heagley DE, Lee JC, Gown AM, Gattuso P, Rotmensch J, Guirguis A, **Dewdney S**, Bitterman P. Immunohistochemical characterization of squamous differentiation and morular metaplasia in uterine endometrioid adenocarcinoma. *Int J Gynecol Pathol* 2013;32(3):435-43. PMID 23518912
20. ***Dewdney SB**, Kizer NT, Andaya A, Babb SA, Luo LJ, Mutch DG, Schmidt AP, Brinton LA, Broaddus RR, Ramirez NC, Huettner P, McMeekin DS, Darcy KM, Ali S, Judson PL, Mannel RS, Lele SB, O'Malley DM, Goodfellow PJ. Uterine Serous Carcinoma: Increased Familial Risk for Lynch-Associated Malignancies. *Cancer Prev Res* 2012;5(3):435-43. PMID 22246618
21. Rimel BJ, Ferda A, Erwin J, **Dewdney S**, Seamon L, DeSimone C, Cotney KK, Huh W, Massad L. Cervicovaginal Cytology in the Detection of Recurrence After Cervical Cancer Treatment. *Obstet and Gynecol* 2011;118(3):548-53. PMID 21860282
22. ***Dewdney S**, Rimel BJ, Thaker PH, Thompson DM, Schmidt A, Mutch DG, Gao F, Goodfellow PJ. Aberrant methylation of the X-linked ribosomal S6 kinase RPS6KA6 (RSK4) in endometrial cancers. *Clin Cancer Research* 2011;17(8):2120-2129. PMID 21372219
23. **Dewdney S**, Benn T, Rimel BJ, Gao F, Saad N, Vedantham S, Mutch DG, Zigelboim I. Inferior vena cava filter placement in the gynecologic patient: A 15-year institutional experience. *Gynecol Oncol* 2011;121(2):344-6. PMID 21276606
24. **Dewdney S**, Mani NB, Zuckerman DA, Thaker PH. Uteroenteric fistula after an uterine artery embolization. *Obstet and Gynecol* 2011;118 (2 Pt2):434-6. PMID 21768845
25. **Dewdney S**, Rimel BJ, Kizer NT, Brooks RA, Massad LM, Zigelboim I. The role of neoadjuvant chemotherapy in the management of patients with advanced stage ovarian cancer: Survey results from members of the Society of Gynecologic Oncologist. *Gynecol Oncol* 2010;119:18-21. PMID 28317007
26. **Dewdney S** and Mutch DG. Evidence-based review of the utility of radiation therapy in the treatment of endometrial cancer. *Women's Health, Future Medicine*. 2010 Sep;6(5):695-703. PMID 20887169
27. Zigelboim I, Zhang C, Kuroki L, Anand M, **Dewdney S**. Discussion: 'Perioperative morbidity model for vaginal hysterectomy' by Heisler et al. *Am J Obstet Gynecol* 2010;202:e1-3. PMID 20113684

28. Kizer NT, Zigelboim I, Case AS, **Dewdney S**, Thaker PH, Massad LS. The role of PET/CT in the management of patients with cervical cancer: Practice patterns of the members of the Society of Gynecologic Oncologists. *Gynecol Oncol* 2009;114:310-4. PMID 19446317
29. **Dewdney S**, Sokoloff M, and Yamada SD. Conservative management of chylous ascites after removal of a symptomatic growing retroperitoneal teratoma. *Gynecol Oncol* 2006;100:608-11.
30. Kennedy CM, **Dewdney S**, and Galask RP. Vulvar Granuloma Fissuratum: A Description of Fissuring of the Posterior Fourchette and the Repair. *Obstet Gynecol* 2005; 105(5, Part 1): 1018-1023. PMID 15863539
31. **Dewdney S**, Kennedy CM, and Galask RP. Leiomyosarcoma of the Vulva: A Case Report. *J Reprod* 2005; 50:630-2. PMID 16220773

Book chapters

Dewdney S, Rotmensch J. Vulvar and Vaginal Cancer. *Cancer Medicine* Wiley, USA 2015

Dewdney S, Thaker P. Patient Surveillance after Cancer Treatment. Chapter 60: Endometrial Carcinoma Surveillance Counterpoint: USA, p. 305-310, Humana Press, Springer Science+Business Media, New York, NY, USA 2013.

Dewdney S, Powell MA. Surgical staging, *Gynecologic Oncology: Clinical Practice and Surgical Atlas* McGraw-Hill, New York, NY, USA 2013.

Peer-Reviewed Abstracts

1. **Dewdney S**, Potter D, Larsen J, Hulick PJ, Riffon M, Monzon FA, Keole SR, Miller RS. Low rates of *BRCA1* and *BRCA2* testing for patients with ovarian cancer in ASCO's CancerLinQ, a real-world database. ASCO Annual Meeting Chicago, Illinois, USA, June 2020.
2. **Dewdney SB**, Wallace S, Lachance J, Sisodia R, Timmins P, Grendys EC, Huh W, Fader AN, Dowdy SC. **Featured poster.** The Society of Gynecologic Oncology's Clinical Outcome Registry database validation process. 51th Annual Meeting on Women's Cancer. Society of Gynecologic Oncology, Toronto, Ontario, Canada March 2020.
3. Mattei LH, Sighoko D, Lee NK, Ansell D, **Dewdney SB**. Racial disparities in survival by in patients with cervical cancer. The Society of Gynecologic Oncology's Clinical Outcome Registry database validation process. 51th Annual Meeting on Women's Cancer. Society of Gynecologic Oncology, Toronto, Ontario, Canada March 2020.

4. Mattei LH, Sighoko D, Lee NK, Ansell D, **Dewdney SB**. Racial disparities in survival by stage and histology in patients with cervical cancer. The Society of Gynecologic Oncology's Clinical Outcome Registry database validation process. 51th Annual Meeting on Women's Cancer. Society of Gynecologic Oncology, Toronto, Ontario, Canada March 2020.
5. Nickles-Fader A, **Dewdney SB**, Wethington S, Wright J. Minimally invasive hysterectomy rates and surgical outcomes in uterine cancer: A society of gynecologic oncology clinical outcomes registry analysis. 51th Annual Meeting on Women's Cancer. Society of Gynecologic Oncology, Toronto, Ontario, Canada March 2020.
6. Shammo JM, Usha L, Richardson KJH, Elliott E, **Dewdney S**, Venugopal P, Cobleigh MA, Kuzel T. Olaparib-Induced Severe Folate Deficiency in Women with Advanced Ovarian and Breast Cancers: First Report and Case Series. *J Clin Oncol* 36, 2018 (suppl; abstr e17540), ASCO Annual Meeting, Chicago, Illinois, June 2018.
7. Levine DA, Dizon DA, Carlson JW, Filiaci VL, Powell MA, Secord AA, Tewari KS, Bender DP, O'Malley DM, Stuckey AR, Moore KN, **Dewdney SB**, Gao J, Dao F, Soslow RA, Lankes HA, Aghajanian CA. Predictive biomarkers of endometrial cancer response: Results from NRG Oncology/Gynecologic Oncology Group study 86P. 49th Annual Meeting on Women's Cancer. Society of Gynecologic Oncology, New Orleans, Louisiana, March 2018.
8. Mallen AR, Filiaci VL, Levine DA, Theiel K, Aghajanian CA, Meng X, Devor E, Moore KN, Powell MA, Secord AA, Tewari KS, Bender DP, Stuckey AR, Fowler JM, **Dewdney SB**, Leslie KK. Evidence of synthetic lethality between bevacizumab and chemotherapy in advanced, p53 null endometrial cancers. 49th Annual Meeting on Women's Cancer. Society of Gynecologic Oncology, New Orleans, Louisiana, March 2018.
9. Hogue C, Barry PN, Kiel KD, Ahmed A, **Dewdney S**, Sen N. SBRT boost as a substitute for brachytherapy in the definitive treatment of locally advanced gynecologic malignancies: An analysis of long term efficacy and late toxicity. Proceedings of the American College of Radiation Oncology. October 2018.
10. Copeland LJ, Brady MF, Burger RA, Rodgers WH, Huang H, Cella D, Fowler JM, Walker JL, Tewari KS, Bender DP, Morris RT, Lowery WJ, Miller DS, **Dewdney SB**, Spirtos NM, Lele SB, Guntapalli SR, Ueland FR, Glaser GE, Mannel RS, DiSaia PJ. A phase III trial of maintenance therapy in women with advanced ovarian/fallopian tube/peritoneal cancer after a complete clinical response to first-line therapy: An NRG oncology study. 48th Annual Meeting on Women's Cancer. Society of Gynecologic Oncology, National Harbor, Maryland, March 2017.
11. **Dewdney SB**, Dolly DR, Mihai A, Fogg L, Guirguis A, Yordan EL, Rotmensch J. Significant delay in the treatment of endometrial cancer based on race and insurance

status. 45th Annual Meeting on Women's Cancer. Society of Gynecologic Oncology, Tampa, Florida, March 2014.

12. Guirguis A, Dolly DR, **Dewdney SB**, Rotmensch J, Bitterman P, Barua A. The clinical relevance of a chemo response assay for treatment of epithelial ovarian cancer. 45th Annual Meeting on Women's Cancer. Society of Gynecologic Oncology, Tampa, Florida, March 2014.
13. Rotmensch JR, **Dewdney SB**. Intraperitoneal administration of alpha-emitting isotopes. 45th Annual Meeting on Women's Cancer. Society of Gynecologic Oncology, Tampa, Florida, March 2014.
14. **Dewdney S**, Jiao Z, Roma A, Gao F, Rimel BJ, Thaker PH, Powell MA, Massad LS, Mutch DG, Zigelboim. The prognostic significance of lymphovascular space invasion in laparoscopic versus abdominal hysterectomies for endometrioid endometrial cancer. 42th Annual Meeting on Women's Cancer. Society of Gynecologic Oncologists, Orlando, Florida, March 2011.
15. Rimel BJ, Ferda A, Erwin J, **Dewdney S**, Seamon L, DeSimone C, Gao F, Huh W, Massad L. Liquid-based cervical cytology in the detection of recurrence after treatment for cervical cancer. 42th Annual Meeting on Women's Cancer. Society of Gynecologic Oncologists, Orlando, Florida, March 2011.
16. **Dewdney S**, Rimel BJ, Kizer NT, Brooks RA, Massad LM, Zigelboim I. The role of neoadjuvant chemotherapy in the management of patients with advanced stage ovarian cancer: Survey results from members of the Society of Gynecologic Oncologist. 40th Annual Felix Rutledge Society Meeting, Chicago, Illinois, June 2010.
17. **Dewdney S**, Benn T, Rimel B, Saad N, Gao F, Vedantham S, Picus D, Massad LS, Mutch DG, Zigelboim I. Anticoagulation after inferior vena cava filter placement in gynecologic oncology patients improves survival. *ASCO Annual Meeting Proceedings 1 (publication only)*. Annual meeting of the American Society of Clinic Oncology, Chicago, Illinois, June 2010.
18. **Dewdney S**, Rimel BJ, Kizer NT, Brooks RA, Massad LM, Zigelboim I. The role of neoadjuvant chemotherapy in the management of patients with advanced stage ovarian cancer: Survey results from members of the Society of Gynecologic Oncologist. 41th Annual Meeting on Women's Cancer. Society of Gynecologic Oncologists, San Francisco, California, March 2010.
19. Rimel B, **Dewdney S**, Ramsey A, Zhang J, Zigelboim I, Brooks R, Thaker P, Mutch D, Massad L. Clinical correlates of death from ovarian cancer: an analysis at 100 days. 41th Annual Meeting on Women's Cancer. Society of Gynecologic Oncologists, San Francisco, California, March 2010.



20. Brooks R, Benn T, Zigelboim I, **Dewdney S**, Rimel B, Thaker P, Zhang J, Powell M, Massad L, Mutch D. Trends in pelvic exenteration in gynecologic oncology. 41th Annual Meeting on Women's Cancer. Society of Gynecologic Oncologists, San Francisco, California, March 2010.
21. **Dewdney S**, Rimel BJ, Powell MA, Thaker PH, Mutch DG, and Goodfellow PJ. Hypermethylation of the RPS6KA6 (RSK4) promoter in endometrioid endometrial cancers and an association with histologic grade. 40th Annual Meeting on Women's Cancer. Society of Gynecologic Oncologists, San Antonio, Texas, February 2009.
22. Kizer N, Zigelboim, Case AS, **Dewdney S**, Thaker PH, and Massad L. The role of PET/CT in the management of patients with cervical cancer: patterns of care among members of the Society of Gynecologic Oncologists. 40th Annual Meeting on Women's Cancer. Society of Gynecologic Oncologists, San Antonio, Texas, February 2009.
23. **Dewdney S**, Lee RC, Temkin S, Lengyel ER, and Yamada SD. Analysis of Outcomes Using an Obturator Fasciocutaneous Flap for Vulvar and Vaginal Reconstruction. 38th Annual Meeting on Women's Cancer. Society of Gynecologic Oncologists, San Diego, California, March 2007.

Speaking Plenary

1. Nickles-Fader A, **Dewdney SB**, Wethington S, Wright J. Minimally invasive hysterectomy rates and surgical outcomes in uterine cancer: A society of gynecologic oncology clinical outcomes registry analysis. 51th Annual Meeting on Women's Cancer. Society of Gynecologic Oncology, Toronto, Ontario, Canada March 2020.
2. **Dewdney S**, Kizer NT, Babb SA, Andaya A, Luo L, David G. Mutch and the GOG-210 study team*. Uterine serous carcinoma: increases familial risk for pancreatic cancer and other lynch- associated malignancies. **Plenary**, 41th Annual Meeting on Women's Cancer. Society of Gynecologic Oncologists, San Francisco, California, March 2010.